Alzheimer’s May Be Cyberonics’ New Frontier; Trial Costs Projected
This article was originally published in The Gray Sheet
Executive Summary
Future indications for Cyberonics' vagus nerve stimulation therapy may include Alzheimer's disease, chronic migraines and anxiety, although a decision on which to pursue first in pivotal trials awaits FDA approval for depression, the firm says